AI could slash MRI contrast doses for breast cancer detection
NCT ID NCT04340180
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 36 times
Summary
This study tested whether artificial intelligence (AI) can help doctors accurately identify breast tumors on MRI scans even when a lower dose of the contrast agent gadolinium is used. Twenty women—half with benign findings and half with breast cancer—participated. The goal is to reduce gadolinium buildup in the brain while maintaining or improving diagnostic accuracy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST BENIGN TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Kirklin Clinic
Birmingham, Alabama, 35249, United States
Conditions
Explore the condition pages connected to this study.